Eyebot, the company behind a 90-second vision test kiosk that provides doctor-verified glasses prescriptions, has raised $20 million in Series A funding led by General Catalyst, with support from AlleyCorp, Baukunst, Village Global, and Ubiquity Ventures.
By eliminating barriers like appointment delays and insurance issues, Eyebot is transforming access to vision care. Its kiosks, located in malls, universities, retail stores, and grocery chains, offer free, quick vision tests followed by prescriptions reviewed by licensed eye doctors.
This funding will allow Eyebot to expand to numerous new retail locations, grow its clinical and engineering teams, and strengthen partnerships with eye care professionals. Since its seed round last year, Eyebot has conducted over 45,000 vision tests and aims to reach over half a million annually.
Eyebot is enhancing the optical experience without replacing eye doctors. Every vision test is doctor-reviewed and has proven to be as accurate as traditional assessments. Eyebot’s prescriptions have shown higher satisfaction scores than the industry average.
To support its growth, Eyebot has formed a Clinical Advisory Board led by Chief Medical Officer Dr. Alexander Martin. In the U.S., over 3 million people have vision impairment, with an additional 8 million experiencing issues from uncorrected refractive errors. Eyebot addresses this gap by offering screenings in convenient locations like malls and pharmacies.
The kiosks also allow new and online eyewear retailers to open smaller storefronts, creating efficient models for care. Established retailers benefit by embedding Eyebot kiosks into their shops, enhancing their capacity for vision testing.
KEY QUOTES:
“Clear vision shouldn’t require months of waiting, high costs, or geographic luck. This funding will help us accelerate our expansion, strengthen our clinical partnerships, and bring accessible vision care to millions more people.”
Matthias Hofmann, co-founder and CEO of Eyebot
“Wider access to high quality eye screenings will lead to more doctor visits, which in turn will allow for earlier detection of diseases and save sight.”
Eyebot’s Chief Medical Officer, Dr. Martin
“We invested in Eyebot because they’ve built something simple, scalable, and incredibly impactful. They’re tackling a real access challenge in healthcare and doing it in a way that supports clinicians, retailers, and consumers alike.”
Caitlin Donovan, Partner at General Catalyst
